Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: Applications of this method for the diagnosis of non-small-cell lung cancer

Uhara, Miho; Matsuda, Kazuyuki; Taira, Chiaki; Higuchi, Yumiko; Okumura, Nubuo; Yamauchi, Kazuyoshi

doi:10.1016/j.cca.2008.11.018

Cited by 12 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PCR methods for detecting exon 19 deletions and L858R in exon 21 were carried out based on the techniques described earlier by Uhara et al. . Changes were, however, introduced, and a description of the two methods and the interpretation criteria used are given below.…”

Section: Methodsmentioning

confidence: 99%

Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?

Lindahl

Sørensen

Jonstrup

et al. 2014

APMIS

View full text Add to dashboard Cite

The identification of EGFR mutations in non-small-cell lung cancer is important for selecting patients, who may benefit from treatment with EGFR tyrosine kinase inhibitors. The analysis is usually performed on cytological aspirates and/or histological needle biopsies, representing a small fraction of the tumour volume. The aim of the present investigation was to evaluate the diagnostic performance of this molecular test. We retrospectively included 201 patients with primary adenocarcinoma of the lung. EGFR mutation status (exon 19 deletions and exon 21 L858R point mutation) was evaluated on both pre-operative biopsies (131 histological and 70 cytological) and on the surgical specimens, using PCR. Samples with low tumour cell fraction were assigned to laser micro-dissection (LMD). We found nine (4.5%) patients with EGFR mutation in the lung tumour resections, but failed to identify mutation in one of the corresponding pre-operative, cytological specimens. Several (18.4%) analyses of the pre-operative biopsies were inconclusive, especially in case of biopsies undergoing LMD and regarding exon 21 analysis. Discrepancy of mutation status in one patient may reflect intra-tumoural heterogeneity or technical issues. Moreover, several inconclusive results in the diagnostic biopsies reveal that attention must be paid on the suitability of pre-operative biopsies for EGFR mutation analysis.

show abstract

Section: Methodsmentioning

confidence: 99%

Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?

Lindahl

Sørensen

Jonstrup

et al. 2014

APMIS

View full text Add to dashboard Cite

show abstract

“…The MBP-QP method was already established for detecting EGFR T790M mutation, which is observed after acquired resistance to EGFR-TKI as described previously. Examinations using allele-specific oligonucleotide PCR were performed, as described elsewhere, 24 to confirm the mutations in two samples where the results of MBP-QP and DS were not consistent. The primer sets used were as follows: 5′-AGGAACGTACTGGTGAAAACACCGC-3′ for the forward primer and 5′-ACACTACCCAGCAGTTTAGCCC-3′ for the reverse primer of the mutant sequence, and 5′-GACTACCCAGCAGTATGGCCA-3′ for the reverse primer of the wild-type sequence.…”

Section: The Mbp-qp Methods and Preparation Of Control Plasmidmentioning

confidence: 99%

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA

Nakamura

Sueoka‐Aragane

Iwanaga

et al. 2012

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Examinations using ASO-PCR were performed as described elsewhere. 30 Primer sets used were as follows: 5Ј-ACCATGCGAAGC-CACACTGACG-3Ј for the forward primer and 5Ј-GC-CGAAGGGCATGAGCTGGA-3Ј for the reverse primer. Direct sequencing was performed using the products amplified by the MBP-QP method.…”

Section: The Mbp-qp Methods and Preparation Of Control Plasmidmentioning

confidence: 99%

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

Nakamura

Sueoka‐Aragane

Iwanaga

et al. 2011

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: Applications of this method for the diagnosis of non-small-cell lung cancer

Cited by 12 publications

References 24 publications

Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?

Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung?

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

Contact Info

Product

Resources

About